A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

August 15, 2018
https://clinicaltrials.gov/ct2/show/NCT03142334
Cancer - Renal Cell
Principal Investigator: Clara Hwang, MD
Renal Cell Cancer, Post Nephrectomy
Accepting Participants